AI Article Synopsis
- Allogeneic hematopoietic stem cell transplantation (HSCT) can effectively cure intermediate and high-risk acute myeloid leukemia, but it has significant complexity, morbidity, and mortality associated with it.
- Advances in understanding the graft versus leukemia effect have led to innovative treatments like Adoptive Immunotherapy, allowing for the use of activated lymphocytes without alloreactivity.
- The infusion of genetically modified T cells and natural killer cells has shown promising results as alternatives to HSCT, particularly in Brazil, where the technology for in vitro expansion of lymphocytes follows Good Manufacturing Practices.
Article Abstract
The allogeneic hematopoietic stem cell transplantation (HSCT) can cure intermediate and high-risk acute myeloid leukemia. Even with the development of strategies to reduce HSCT toxicity, this is still a complex treatment with high morbidity and mortality. Knowledge of the graft versus leukemia effect of HSCT has prepared the way for the development of Adoptive Immunotherapy or in vitro expansion of activated lymphocytes without alloreactivity, with subsequent intravenous infusion. The infusion of genetically modified T lymphocytes and haploidentical natural killer cells has been tested as an alternative to HSCT with very interesting results worldwide and in Brazil, as we not only have the technology of in vitro expansion of clinical grade lymphocytes available, but also do it according to the Good Manufacturing Practices that have been determined internationally.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/1806-9282.62.suppl1.23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!